PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Bio-Modeling Systems

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Bio-Modeling Systems Announces Official Launch of Pherecydes-Pharma - Pherecydes-Pharma: The world's first biotech company created from an integrative biology research program has finalized proofs of concept and gears up for business development. A new success for Bio-Modeling Systems
Bio-Modeling Systems Announces Official Launch of Pherecydes-Pharma

 

NewswireToday - /newswire/ - Paris, Ile-de-France, France, 2009/10/16 - Pherecydes-Pharma: The world's first biotech company created from an integrative biology research program has finalized proofs of concept and gears up for business development. A new success for Bio-Modeling Systems.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The world's first biotech company created from an integrative biology research program has finalized proofs of concept and gears up for business development.

1. During summer 2009, the Pherecydes-Pharma team finalized the development and the validation of its three patented innovations. BMSystems invented and designed all 3 technologies, using its predictive integrative biology process (CADI™). Pherecydes Pharma did the job to validate the concepts and today industrial applications are ready to go.
This demonstrates once again the strength of CADI™, to deliver patentable and immediately applicable results.

2. Pherecydes-Pharma achieved a first 1.15 M € financial round and was granted 500 K€ from Oséo, the French governmental innovation agency.

3. Pherecydes-Pharma recruited Dr. Jérôme Gabard, its new CEO to launch the industrial and business development. “Since incorporation, Pherecydes Pharma has been running underground, to successfully develop revolutionary technologies using phages and accelerated protein evolution” said Jérôme. "Interestingly enough, the company has been spotted by overseas conference organizations and invited to speak at Biodetection Technologies (2008) in Atlanta (USA), at the Edinburg Phage World Conference (2008) and the NSTI Nanotechnology Conference (2009) in Houston (TX, USA)". "But until late September 2009, scientists were fully focused on the validation and the development of our disruptive technologies and mostly silent about our activities". "The time has come to communicate” said Jérôme “because Pherecydes Pharma holds very exciting nanotechnology tools, with applications in a in a wide variety of fields”.

Fields of application are numerous.
· Create a new generation of fast detection tools for industrial, environment and medical diagnostics,
· Develop new therapeutic solutions against bacterial infections, including an elegant answer for killing current resistant strains and the likely new ones to occur,
· Produce new disinfection products for controlling infectious agents, including nosocomial threats,
· Develop nanodevices for preventing the risk of a pandemic bioterrorism infection,
· To design new types of formulation using a living or dead phage for transporting a key molecule,
· Offer a process for generating active analogues of bioproducts with applications in therapeutics, crop protection, and industrial enzymes.

Pherecydes-Pharma and Bio-Modeling Systems are participating to BIO Europe 2009 in Vienna from November 1-4, 2009. BioXplain, first Open Platform for Iterative, Predictive and Integrative Biology will be introduced during the conference, with BMSystems partners: BioXpr and Kayentis

About Bio-Modeling Systems
BMSystems is a research-based biotech company that creates CADI™ (Computer Assisted Deductive Integration) models to harness & explain the non-linear mechanisms of life and disease, thus revealing “pertinent” biomarkers & therapeutic targets.
CADI™ is a modeling approach based on negative selection processes. Since 2004, biological models generated using CADI™ have repeatedly allowed researchers to take the best possible decisions, for the best possible results, in a minimum of time and resources addressing key R&D challenges such as:

1. Disease/pathology understanding / redefinition, new therapeutic strategies, new associations of existing molecules
2. Identification/selection of pertinent predictive Biomarkers
3. R&D programs evaluation and validation
4. Predictive efficacy and safety profiles
5. Drug (re)positioning /(re)profiling/ rescue
6. Proposition of new bioproduction processes through micro-organisms’ modifications, …

Thus, leading to better, faster, cheaper and safer life sciences R&D processes.

The results obtained with CADI™ in the Creutzfeldt-Jakob (neurodegenerative) disease research program will be presented at the 3rd edition of the European scientific conference Be Live IT in Brussels (October 20-21, 2009). This work received in 2009 a Bio-IT World Best Practices Award from the Cambridge Healthtech Institute. Please join us there.

About Pherecydes Pharma
Pherecydes-Pharma SA (pherecydes-pharma.com) is a bio-nanotechnology Company established in December 2006. Shareholders are Financière de Brienne and Fond Sécurité (VC funds advised by ACE Management), as well as Bio-Modeling Systems. For more details, we warmly invite you to discover Pherecydes-Pharma's new website.

Dr. Jérôme Gabard (PhD) joined Pherecydes Pharma on September 1st 2009. Since the late eighties, Dr. Gabard has been working in a variety of life sciences areas. He started at the bench, in plant biotechnology, at E.I. DuPont De Nemours and Co., Wilmington (DE, USA). In the mid nineties, he moved to research program supervision and project development at DuPont de Nemours SA (France) ERDC. Then, he drove a diagnostic product development at Qualicon. From 2001 to 2004, he was CEO of Euroclide SA (a GPCR receptor screening specialized Co.), which became part of Faust Pharmaceuticals, (today Domain Therapeutics), through merger acquisition. Until August 2009, he was holding the position of Life Sciences Director at The MarkeTech Group, the international marketing consulting firm dedicated to market research for life sciences products.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Bio-Modeling Systems

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Bio-Modeling Systems Announces Official Launch of Pherecydes-Pharma

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Manuel Gea - BMSystems.net 
+33(0)6 83 06 12 72 manuel.gea[.]bmsystems.net
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Bio-Modeling Systems securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Bio-Modeling Systems / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine
Somatuline® Autogel® 120 Mg Receives Japanese Approval for A New Indication for the Treatment of Gastro-entero-pancreatic Neuroendocrine Tumors
OTC Topical Drugs Market Size will Grow Profitably in the Near Future 2017-2025 Finds PMR
Bioinformatics Market Size to Expand at 20.4% CAGR through 2020 Reports Persistence Market Research
Australia Nitric Acid Market Expected to Reach at Value of $1.3B by 2024 End Says PMR
Commodity Chemicals Market Projected to be Resilient by 2020 Says Persistence Market Research
Cell Expansion Market Set to Garner Staggering Revenues by 2025 Reports PMR
Soft Tissue Sarcoma Treatment Market Revenue Predicted To Go Up by 2025 Finds Persistence Market Research
Persistence Market Research Publishes Biopharmaceutical Membrane Filtration Market Forecast Over 2017-2025
Global Tablet Processing & Packaging Equipment Market to Reach USD 5,268.8 Million by 2022

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  NAKIVO, Inc.

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)